Abstract
Mastitis is the most burdensome concern for the dairy cattle industry. Antimicrobials are often prophylactically administered to dairy cows at dry-off to reduce the risk of intramammary infection during the dry period and subsequent lactation. Mastitis incidence has increased in dairy heifers after calving, leading to extralabel drug use of various dry cow products, including intramammary ceftiofur hydrochloride. However, the pharmacokinetics and efficacy of this application have yet to be studied. This study aimed to compare the pharmacokinetics and efficacy following no treatment, a non-antimicrobial teat sealant, or a single dose of intramammary ceftiofur given at 21 or 14 days before expected calving. We hypothesized that milk collected following dosing would contain drug residues below the FDA tolerance of 100 ng/mL by calving, and heifers within the ceftiofur treatment groups would have lower somatic cell counts (SCCs) than heifers in the teat sealant and nontreatment control groups. Following treatment or no treatment of 24 prepartum heifers, milk samples were collected until 21 days after calving. Somatic cell counts and ceftiofur concentrations were assessed utilizing a cell counter and UPLC/MS detection, respectively. Ceftiofur administration did not significantly reduce SCCs compared to other groups by days 7, 14, or 21. For heifers treated 14 and 21 days prior to calving, milk had a maximum ceftiofur concentration of 8.14 ± 6.24 and 4.20 ± 5.07 ng/mL 48 h into lactation, respectively. The minimal ceftiofur concentrations in milk collected from these heifers indicate that administration of ceftiofur 14 or 21 days before calving is unlikely to lead to violative residues. However, it is essential that regional regulations regarding the use of ceftiofur are adhered to.